Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500
If you need additional assistance or information regarding the company, please
send an Email to:
webinfo@neurochem.com.
December 11, 2002
- Annual General and Special Shareholders' Meeting
Neurochem has successfully completed the enrollment of patients for the ongoing
Fibrillex™ trial.
At its annual and special meeting of shareholders today, Neurochem Inc. (TSX : NRM) announced
that it has successfully completed the enrollment of the 150 patients required for its pivotal
phase II/III trial...
(learn more by clicking here)
December 11, 2002
- Neurochem announces multi-million dollar investment by Picchio Pharma Inc.
Neurochem Inc. (TSX : NRM) announced today that a subsidiary of Picchio Pharma Inc. has
agreed to make an investment in Neurochem of $8.148 million with the purchase of 1.2
million units of Neurochem...
(learn more by clicking here)
November 28, 2002
- Dr. Louis R. Lamontagne announces decision to step down.
Dr. Francesco Bellini chosen CEO of Neurochem.
Neurochem Inc. (TSX : NRM) today announced that Dr. Louis R. Lamontagne, President and
CEO, will step down at the next annual general meeting of shareholders to be held December
11, 2002...
(learn more by clicking here)
November 18, 2002
- Neurochem Announces First Quarter Results for Fiscal 2003.
The Company realizes pivotal corporate and clinical milestones.
Neurochem Inc. (TSX : NRM) today announced its results for the first quarter of fiscal
2003, ended September 30, 2002. The Company reported revenues of $253,000 and a net loss
of $3,962,000 or...
(learn more by clicking here)
November 18, 2002
- New analyst at Desjardins Securities initiates coverage of Neurochem.
Neurochem Inc. (TSX : NRM) announced today that Dr. Laurence Terrisse-Rulleau, Vice
President, Senior Analyst Biotechnology at Desjardins Securities has initiated coverage
of the Company. Research...
(learn more by clicking here)
November 5, 2002
- Neurochem presents further scientific evidence of disease modifying activity with its
drug candidate for the treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy.
Two presentations at 32nd Annual Society for Neurosciences Meeting in Orlando.
Neurochem Inc. (TSX : NRM) presented its research findings in an oral and a poster
presentation at the 32nd Annual Society for Neurosciences meeting in Orlando,
Florida. In an oral presentation...
(learn more by clicking here)
October 29, 2002
- Neurochem announces webcast of presentation at The 4th Annual MASS Opportunities
Investor Conference.
Neurochem Inc. (TSX : NRM) announced today that its presentation at The 4th Annual Mass
Opportunities Investor Conference will be webcast live via the MASS Opportunities conference
Web site at...
(learn more by clicking here)
October 25, 2002
- Investigational New Drug in the U.S. for Cerebril™ Takes Effect and Signals
Initiation of Phase II Clinical Trial.
Neurochem announces positive progress for its Clinical Program on Hemorrhagic Stroke
due to Cerebral Amyloid Angiopathy.
Neurochem Inc. (TSX : NRM) announced today that its Investigational New Drug (IND)
application for Cerebril™, the Company's lead drug candidate for the prevention of
recurrent Hemorrhagic Stroke due to...
(learn more by clicking here)
October 9, 2002
- Neurochem announces appointment of two new Board Members, Mr. Ronald M. Nordmann and
Mr. Peter Kruyt.
Neurochem Inc. (TSX : NRM) is pleased to announce the appointments of Mr. Ronald M.
Nordmann, Co-President, Global Health Associates, LLC, and Mr. Peter Kruyt, Vice-President
of Power Corporation...
(learn more by clicking here)
October 8, 2002
- Neurochem appoints Claude Michaud New Senior Vice-President Finance & Chief
Financial Officer
Neurochem Inc. (TSX : NRM) is pleased to announce the appointment of Mr. Claude Michaud
as Senior Vice-President Finance and Chief Financial Officer....
(learn more by clicking here)
September 30, 2002
- Neurochem announces positive development for its Alzheimer's Disease program.
IND in the U.S. for Alzhemed™ Takes Effect and Phase II Clinical Trial Gets
Initiated.
Neurochem Inc. (TSX : NRM) announced today that its IND application for the drug
candidate Alzhemed™ to be used in the treatment of Alzheimer's Disease (AD) has
been cleared by the U.S. ...
(learn more by clicking here)
September 25, 2002
- Neurochem files Investigational New Drug application for Cerebril™ to treat
Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy.
Neurochem Inc. (TSX : NRM) announced today that it has filed an Investigational New Drug
(IND) application with the U.S. Food and Drug Administration for Cerebril™, the
Company's candidate for the...
(learn more by clicking here)
September 19, 2002
- Neurochem Inc. Announces 2002 Year-end Results.
Strategic investment by Picchio Pharma and significant advances in Clinical Trial
Programs.
Neurochem Inc. (TSX : NRM) announced today its results for the fiscal year, ended June 30,
2002, including a strategic investment by Picchio Pharma Inc., important clinical advances
for Alzhemed™ with the...
(learn more by clicking here)
August 29, 2002
- Neurochem files Investigational New Drug application for Alzhemed™ to treat
Alzheimer's Disease.
Neurochem Inc. (TSX : NRM) announced today that it has filed an Investigational New Drug
(IND) application with the U.S. Food and Drug Administration for Alzhemed™, the
company's lead candidate...
(learn more by clicking here)
August 28, 2002
- Neurochem receives unanimous recommendation by independent data safety monitoring board
to continue trial for Fibrillex™.
Neurochem Inc. (TSX : NRM) announced today the unanimous recommendation by its
independent Data Safety Monitoring Board (DSMB) to continue the pivotal Phase II/III
trial for Fibrillex™, a...
(learn more by clicking here)
July 29, 2002
- Neurochem completes transaction with Picchio Pharma Inc.
Neurochem Inc. (TSX : NRM) announced today the closing of the transaction by Picchio Pharma
Inc. for the acquisition of 2.8 million units of Neurochem at a cost of $2.50 per unit, for
a total of $7 million. The...
(learn more by clicking here)
July 23, 2002
- Neurochem scientists report on multiple research and therapeutic programs for Alzheimer's Disease.
Data presented at the 8th International Conference on Alzheimer's Disease and Related
Disorders, in Stockholm, Sweden.
Neurochem Inc. (TSX : NRM) is presenting novel results at the 8th International Conference
on Alzheimer's Disease and Related Disorders, in Stockholm, Sweden (July 20-25, 2002). The
Company...
(learn more by clicking here)
June 19, 2002
- Dr. Francesco Bellini to Join Board as Chairman.
Neurochem announces multi-million dollar investment by Picchio Pharma Inc.
Neurochem Inc. (TSX : NRM) announced today that Picchio Pharma Inc. has agreed to make an
initial investment in Neurochem of $7 million with the purchase of 2.8 million units of
Neurochem at a cost of $2.50...
(learn more by clicking here)
May 15, 2002
- Neurochem Announces Third Quarter Results.
Continued progress in clinical programs and signing of a testing & option
agreement with Immtech-International.
Neurochem Inc. (TSX : NRM) announced today its results for the third quarter ended March 31,
2002, as well as pre-IND meetings for the Phase II clinical trials for Alzhemed™ and
Cerebril™, and the signing...
(learn more by clicking here)
May 6, 2002
- Neurochem and Immtech enter into a testing and option agreement.
Evaluation of New Class of Compounds with Anti-Amyloid Potential.
Neurochem Inc. (TSX : NRM) and Immtech International, Inc., (NASDAQ : IMMT) announced today
that the companies have entered into a testing and option agreement which allows Neurochem to...
(learn more by clicking here)
April 9, 2002
- Neurochem identifies a series of compounds for the potential treatment of epilepsy.
Results presented at Sixth Eilat Conference on New Anti-Epileptic Drugs.
Neurochem Inc. (TSX : NRM) in collaboration with one of the Company's Principal Investigators
Dr. Donald F. Weaver from Queen's University (Kingston, Canada), presented preclinical
studies showing...
(learn more by clicking here)
April 4, 2002
- Neurochem presents Phase I Clinical Trial results and proof-of-concept data for
drug candidate Alzhemed™ for Alzheimer's Disease.
Reported at the 7th International Geneva/Springfield Symposium on Advances in
Alzheimer's Therapy.
Neurochem Inc. (TSX : NRM) presented promising results of three Phase I clinical
studies with Alzhemed™, Neurochem's lead drug candidate for the treatment of
Alzheimer's Disease. The data...
(learn more by clicking here)
February 19, 2002
- Neurochem receives U.S. patent for amyloid program.
Neurochem Inc. (TSX : NRM) has been issued a U.S. patent relating to the Company's
industry-leading amyloid technology program. The patent, No. 6,329,356, covers the use
of phosphonocarboxylate...
(learn more by clicking here)
February 13, 2002
- Neurochem Annonces Second Quarter Results.
Continued progress in clinical programs and expanded intellectual property
protection.
Neurochem Inc. (TSX : NRM) announced today its results for the second quarter ended
December 31, 2001, as well as continued progress in its drug development programs and
patent portfolio. The...
(learn more by clicking here)
February 7, 2002
- Desjardins securities initiates coverage of Neurochem
Neurochem Inc. (TSX : NRM) announced today that Dr. George Mahmourides, Biotech analyst
at Desjardins Securities has initiated coverage of the Company. Research reports are also
available from...
(learn more by clicking here)
January 29, 2002
- Neurochem scientists release finding on in vivo inhibition of amyloid formation and
deposition in Alzheimer's Disease research prognam.
Researchers present data at the 5th International Symposium on the Medicinal Chemistry
of Neurodegenerative Diseases.
Neurochem Inc. (TSX : NRM) presented new data this week related to understanding the
biology of Alzheimer's Disease at the 5th International Symposium on the Medicinal
Chemistry of Neurodegenerative...
(learn more by clicking here)
|
2008
Archives 2001
